Please ensure Javascript is enabled for purposes of website accessibility
Athersys Stock Quote

Athersys (NASDAQ: ATHX)

Price as of September 30, 2022, 3:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Athersys Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ATHX -94.44% -96.41% -48.55% -99%
S&P -16.76% +42.32% +7.31% +140%

Athersys Company Info

Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life.

News & Analysis

Here's Why Athersys Stock Is Soaring Today
Maxx Chatsko  |  Jun 25, 2020

The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.

Here's Why Athersys Rose 26.5% in May
Maxx Chatsko  |  Jun 9, 2020

The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.

Here's Why Athersys Tumbled 23.3% in April
Maxx Chatsko  |  May 4, 2020

The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?
Maxx Chatsko  |  Apr 28, 2020

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.

Athersys Stock Tumbles as Much as 27.7% on a Public Offering
Maxx Chatsko  |  Apr 16, 2020

The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.

Here's Why Athersys Rose as Much as 15.2% Today
Maxx Chatsko  |  May 14, 2019

The FDA has given the company's lead drug platform a potential leg up in development.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.